Columbus, Ohio, USA, November 12, 2026
Andelyn Biosciences has announced a strategic partnership with South Korean biotechnology company Celliaz Co., Ltd. to advance the development and manufacturing of CLZ002, an investigational adeno-associated virus (AAV)-based gene therapy being developed for the treatment of retinitis pigmentosa (RP). Under the agreement, Andelyn will provide integrated development and manufacturing services using its proprietary AAV Curator® Suspension Platform, supporting the production of AAV2 vectors and plasmids required for investigational new drug (IND)-enabling studies and a planned Phase 1/2 clinical trial. The collaboration represents an important development in the cell and gene therapy manufacturing sector, combining Celliaz’s innovative retinal regeneration research with Andelyn’s expertise in viral vector development and manufacturing. Retinitis pigmentosa is a group of inherited retinal disorders characterised by progressive damage to light-sensitive cells in the retina, potentially leading to severe vision impairment and blindness. The condition affects more than 3 million people worldwide, while currently available treatment options remain limited. Through this partnership, both companies aim to accelerate the development of a potential treatment that could address multiple genetic forms of the disease.
CLZ002 Targets Retinal Regeneration Through PROX1
Celliaz is developing CLZ002 using a distinct therapeutic approach designed to restore the retina’s natural regenerative capacity rather than targeting individual disease-causing genetic mutations. The investigational therapy uses an AAV2 capsid-based delivery system and is designed to prevent the transfer of a protein called PROX1 into Müller glia, specialised retinal cells that retain regenerative potential. According to Celliaz, PROX1 suppresses the regenerative activity of Müller glia after being transferred from neighbouring retinal cells. By blocking this transfer, CLZ002 aims to reactivate the intrinsic regenerative capabilities of these cells and support the repair of damaged retinal tissue. This approach is particularly relevant because retinitis pigmentosa can result from mutations in more than 90 different genes, making the development of individual gene-specific therapies challenging. A gene-agnostic strategy could potentially extend treatment opportunities to a broader population of patients affected by different genetic causes of the disease. However, CLZ002 remains an investigational therapy, and its safety and effectiveness will need to be established through appropriate preclinical and clinical studies. The planned development programme will provide an opportunity to evaluate its therapeutic potential and support future clinical investigation.
Andelyn to Provide AAV2 Vector and Plasmid Manufacturing
Under the partnership, Andelyn Biosciences will provide end-to-end development and manufacturing services through its proprietary Curator® Suspension Platform. The manufacturing programme will include AAV2 viral vector and plasmid production to support IND-enabling development activities and preparation for clinical testing. Andelyn’s integrated manufacturing capabilities are intended to support the transition of CLZ002 from early development towards clinical-stage production. The company specialises in cell and gene therapy contract development and manufacturing, offering services that include plasmid engineering, process development, analytical development, viral vector manufacturing and current Good Manufacturing Practice (cGMP) production. Its manufacturing expertise is particularly relevant for AAV-based therapies, which require specialised production processes, quality controls and analytical testing to ensure consistency and product quality. Andelyn reports more than 20 years of experience in the sector and has produced materials supporting over 500 cGMP batches and 85 global clinical trials, including an FDA-approved AAV gene therapy. The Curator® platform provides a manufacturing framework designed to support programmes across different development stages, helping biotechnology companies advance complex gene therapy candidates towards clinical evaluation. Financial terms and specific manufacturing timelines for the Celliaz collaboration were not disclosed.
Partnership Advances Rare Disease Gene Therapy Development
The collaboration reflects the growing importance of strategic partnerships between biotechnology developers and specialised contract development and manufacturing organisations (CDMOs) in advancing innovative genetic medicines. For emerging biotechnology companies, access to experienced viral vector manufacturing partners can help address technical challenges associated with process development, product characterisation, analytical testing and clinical supply preparation. Celliaz plans to advance CLZ002 through IND-enabling studies before initiating its planned Phase 1/2 clinical trial. The company is headquartered in Daejeon, South Korea, and focuses on developing regenerative therapies for retinal degenerative diseases based on research originating from the Korea Advanced Institute of Science and Technology (KAIST). Andelyn’s manufacturing support is expected to play an important role in preparing the investigational programme for regulatory submission and subsequent clinical development. The partnership also strengthens Andelyn’s involvement in supporting biotechnology programmes from South Korea and expands its work in ophthalmology and rare disease gene therapy. Although CLZ002 has not yet entered the planned clinical trial stage, the agreement represents a meaningful development milestone for its manufacturing and preclinical preparation. By combining AAV manufacturing expertise with an innovative gene-agnostic therapeutic strategy, Andelyn and Celliaz aim to advance a potential new treatment approach for patients living with retinitis pigmentosa.
Source: Andelyn Biosciences press release



